Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acute myeloid leukemia.

Richard M Stone1, Margaret R O'Donnell, Mikkael A Sekeres

  • 1Dana-Farber Cancer Institute, Boston MA 02115-6084, USA.

Hematology. American Society of Hematology. Education Program
|November 25, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Do We Sin When Treating Patients with Higher-Risk Myelodysplastic Syndromes?

Transplantation and cellular therapy·2026
Same author

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

Blood cancer journal·2026
Same author

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

HemaSphere·2026
Same author

Myelodysplastic syndrome with concomitant <i>SF3B1</i> mutation and deletion of chromosome 5 long arm: outcomes and response to treatment.

Haematologica·2026
Same author

Increased duration of time without transfusion reliance with imetelstat vs placebo in the phase 3 IMerge trial.

Blood neoplasia·2026
Same author

Not guilty by association: myelodysplasia-related mutations in AML.

Leukemia·2026
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Despite advances, adult acute myeloid leukemia (AML) survival remains poor. This chapter explores current challenges and emerging targeted therapies for AML management, focusing on optimal induction, postremission strategies, and special considerations for older patients.

Area of Science:

  • Hematology
  • Oncology
  • Internal Medicine

Background:

  • Acute myeloid leukemia (AML) in adults has seen limited survival improvements despite advances in understanding its pathophysiology.
  • Current treatments for AML are often devastating for older adults, with low cure rates even in younger adults (18-60).

Purpose of the Study:

  • To discuss the challenges in managing adult acute myeloid leukemia (AML).
  • To explore optimal induction and postremission therapies, including stem cell transplantation.
  • To address special considerations for older AML patients and the development of targeted therapies.

Main Methods:

  • Review of state-of-the-art AML therapy, including a shift towards a genetically based classification system.
  • Discussion of ongoing randomized cooperative group trials addressing induction anthracycline dose, drug-resistance modulators, and pro-apoptotic agents.

Related Experiment Videos

  • Exploration of developmental therapeutics such as drug resistance modulation, anti-angiogenic strategies, immunotherapy, and signal transduction inhibitors.

    • Main Results:

    • Advances in stem cell transplantation, including expanded donor pools and nonmyeloablative transplant, make allogeneic options more viable.
    • Risk-adapted approaches to stem cell transplantation in AML patients in first remission are outlined.
    • Outcome data for older AML patients, including specific therapies and the role of drug-resistance modulators, are summarized.

    Conclusions:

    • Optimal induction and postremission therapy choices for adult AML remain critical areas of investigation.
    • Stem cell transplantation, particularly allogeneic nonmyeloablative transplant, offers a more viable option for select AML patients.
    • Tailoring treatment strategies for older AML patients, considering unique biological and therapeutic factors, is essential for improving outcomes.